Outpatient SUI treatment approved for marketing

Article

The FDA has approved for marketing Novasys Medical's Renessa System, a treatment for stress urinary incontinence due to hypermobility in women unresponsive to conservative care who are not candidates for surgical therapy.

The FDA has approved for marketing Novasys Medical's Renessa System, a treatment for stress urinary incontinence due to hypermobility in women unresponsive to conservative care who are not candidates for surgical therapy. The 20-minute outpatient treatment involves applying controlled heat to tissue in the lower urinary tract, denaturing collagen at multiple small sites to increase tissue resistance to involuntary leakage during increased intra-abdominal pressure.

A multicenter clinical trial in 170 women who underwent the Renessa treatment resulted in reduced incontinence episodes, pad use, and leak severity for the majority of study participants, Novasys said.

For more information, visit www.novasysmedical.com.

Related Videos
Eiftu S. Haile, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr_Microbe - stock.adobe.com
Todd M. Morgan, MD, answers a question during a Zoom video interview
DNA strands | Image Credit: ©  Matthieu - stock.adobe.com
Doctor consulting with patient | Image Credit: © Khunatorn - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.